| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
ORIGINAL RESEARCH COMMUNICATION |
1 From the Center for Human Nutrition, David Geffen School of Medicine (SMH, YN, NHL, GDT, RRM, VLWG, and DH) and the Department of Biostatistics (HW), School of Public Health, University of California, Los Angeles
Background: Green and black tea polyphenols have been extensively studied as cancer chemopreventive agents. Many in vitro experiments have supported their strong antioxidant activity. Additional in vivo studies are needed to examine the pharmacokinetic relation of absorption and antioxidant activity of tea polyphenols administered in the form of green or black tea or tea extract supplements.
Objective: The purpose of this study was to compare the pharmacokinetic disposition of tea polyphenols and their effect on the antioxidant capacity in plasma 8 h after a bolus consumption of either green tea, black tea, or a green tea extract supplement.
Design: Thirty healthy subjects were randomly assigned to 3 different sequences of green tea, black tea, or a green tea extract supplement in a 3 x 3 crossover design with a 1-wk washout period in between treatments.
Results: Flavanol absorption was enhanced when tea polyphenols were administered as a green tea supplement in capsule form and led to a small but significant increase in plasma antioxidant activity compared with when tea polyphenols were consumed as black tea or green tea. All 3 interventions provided similar amounts of (–)-epigallocatechin-3-gallate.
Conclusions: Our observations suggest that green tea extract supplements retain the beneficial effects of green and black tea and may be used in future chemoprevention studies to provide a large dose of tea polyphenols without the side effects of caffeine associated with green and black tea beverages.
Key Words: Bioavailability • pharmacokinetics • black tea • green tea • antioxidant capacity • tea flavanols • trolox equivalent antioxidant capacity
This article has been cited by other articles:
|
|
 |
|
  A. S. Tsao, D. Liu, J. Martin, X.-m. Tang, J. J. Lee, A. K. El-Naggar, I. Wistuba, K. S. Culotta, L. Mao, A. Gillenwater, et al. Phase II Randomized, Placebo-Controlled Trial of Green Tea Extract in Patients with High-Risk Oral Premalignant Lesions Cancer Prevention Research, November 1, 2009; 2(11): 931 - 941. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Hughes, I. C. Arts, T. Ambergen, H. A. Brants, P. C Dagnelie, R A. Goldbohm, P. A van den Brandt, and M. P Weijenberg Higher dietary flavone, flavonol, and catechin intakes are associated with less of an increase in BMI over time in women: a longitudinal analysis from the Netherlands Cohort Study Am. J. Clinical Nutrition, November 1, 2008; 88(5): 1341 - 1352. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. W. Laschke, C. Schwender, C. Scheuer, B. Vollmar, and M. D. Menger Epigallocatechin-3-gallate inhibits estrogen-induced activation of endometrial cells in vitro and causes regression of endometriotic lesions in vivo Hum. Reprod., October 1, 2008; 23(10): 2308 - 2318. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Henning, J. J. Choo, and D. Heber Nongallated Compared with Gallated Flavan-3-ols in Green and Black Tea Are More Bioavailable J. Nutr., August 1, 2008; 138(8): 1529S - 1534S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kuriyama The Relation between Green Tea Consumption and Cardiovascular Disease as Evidenced by Epidemiological Studies J. Nutr., August 1, 2008; 138(8): 1548S - 1553S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. S. Stote and D. J. Baer Tea Consumption May Improve Biomarkers of Insulin Sensitivity and Risk Factors for Diabetes J. Nutr., August 1, 2008; 138(8): 1584S - 1588S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T.-P. Ng, L. Feng, M. Niti, E.-H. Kua, and K.-B. Yap Tea consumption and cognitive impairment and decline in older Chinese adults Am. J. Clinical Nutrition, July 1, 2008; 88(1): 224 - 231. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. McKay and J. B. Blumberg Roles for Epigallocatechin Gallate in Cardiovascular Disease and Obesity: An Introduction J. Am. Coll. Nutr., August 1, 2007; 26(4): 362S - 365S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Carlson, B. A. Bauer, A. Vincent, P. J. Limburg, and T. Wilson Reading the Tea Leaves: Anticarcinogenic Properties of (-)-Epigallocatechin-3-Gallate Mayo Clin. Proc., June 1, 2007; 82(6): 725 - 732. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Ehrnhoefer, M. Duennwald, P. Markovic, J. L. Wacker, S. Engemann, M. Roark, J. Legleiter, J. L. Marsh, L. M. Thompson, S. Lindquist, et al. Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models Hum. Mol. Genet., September 15, 2006; 15(18): 2743 - 2751. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Henning, W. Aronson, Y. Niu, F. Conde, N. H. Lee, N. P. Seeram, R.-P. Lee, J. Lu, D. M. Harris, A. Moro, et al. Tea Polyphenols and Theaflavins Are Present in Prostate Tissue of Humans and Mice after Green and Black Tea Consumption J. Nutr., July 1, 2006; 136(7): 1839 - 1843. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
